Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTaking Wegovy for weight loss means starting at a low dose, injecting it once a week under the skin, and increasing gradually under clinical supervision until you reach your maintenance dose. Semaglutide — the active ingredient in Wegovy — is a prescription-only medicine, so a prescriber assesses your suitability before any treatment begins. That clinical step is not a formality; it shapes how the medicine is used and whether it is right for you specifically. This page sets out exactly what the treatment process looks like and what the key decisions along the way really involve.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The first practical decision is choosing which day of the week to inject. It does not have to be Monday, and it definitely does not have to align with a symbolic fresh start. Some people anchor it to something predictable, like a weekend morning or a day they are reliably at home. What matters is that the gap between doses stays close to seven days. You can shift the day by a day or two if something comes up (a holiday, a work trip, even a bank holiday delivery landing differently than expected) but the principle is consistency.
The injection itself goes under the skin in the abdomen, the top of the thigh or the outer upper arm. Rotating sites from week to week reduces the chance of localised reactions at the skin. The step-by-step process for giving the injection is worth reading through before your first pen arrives, particularly if you have not self-injected before. Most people find it straightforward by their second or third dose. The pen is pre-filled and pre-set; you do not draw up a dose or measure anything.
Storage is straightforward too: keep pens refrigerated at 2–8°C until you need them. For exact guidance on the room-temperature window if you need the pen out of the fridge for travel, the Wegovy Patient Information Leaflet on the eMC is the definitive reference, never rely on a third-party summary for that detail.
The dose-escalation path exists for a reason that is easy to underestimate: it is primarily about tolerability, not therapy. The 0.25 mg starting dose gives your digestive system time to adjust to semaglutide before the dose moves to a level where meaningful appetite suppression kicks in. Skipping rungs or escalating faster than the schedule allows tends to produce worse nausea without delivering better outcomes. Your prescriber controls the timing of increases, and a clinical review happens before each one.
The standard UK schedule under the Wegovy licence runs: 0.25 mg for weeks 1–4, 0.5 mg for weeks 5–8, 1.0 mg for weeks 9–12, 1.7 mg for weeks 13–16, then 2.4 mg as the maintenance dose from week 17 onwards. If the 7.2 mg pen is clinically appropriate (the MHRA approved a dedicated single-dose 7.2 mg Wegovy pen in April 2026 as the maximum dose for eligible patients) the titration continues beyond 2.4 mg under prescriber direction. Availability of specific doses and pen formats is confirmed at consultation, not assumed.
If side effects at a particular step are significant, your prescriber may suggest staying at that dose for an additional four weeks rather than moving up. That is not a setback; it is the intended flexibility built into the schedule. How frequently you inject and the timing of dose changes are two related questions the prescribers at nume address during every clinical review.
Nausea is the most commonly reported side effect of semaglutide, and it is worth knowing that it tends to be worst in the first week after starting or after a dose increase, then fades. The NHS semaglutide medicines page lists the full side-effect profile: nausea, vomiting, diarrhoea, constipation, indigestion, burping and fatigue are all reported, alongside headache, dizziness and injection-site reactions. Most are mild to moderate and transient.
Practical adjustments that many patients find helpful include eating smaller meals, going slowly with richer or fattier foods, and staying well hydrated, particularly important if diarrhoea or vomiting occurs. Protein intake tends to matter more on a reduced appetite than usual; you are eating less, so the quality of what you eat carries more weight, including decisions like whether foods such as steak fit into your meals while on Wegovy. None of that is a clinical prescription for what you personally should eat; it is worth discussing with your prescriber.
More serious signals require prompt medical attention: severe stomach pain that extends through to the back, with or without vomiting, can indicate pancreatitis, a rare but recognised risk with GLP-1 medicines. Gallbladder symptoms, signs of a serious allergic reaction and significant dehydration are also reasons to seek help urgently rather than managing at home. Suspected side effects can be reported directly to the MHRA via the Yellow Card scheme.
Wegovy is licensed for adults with a BMI of 30 or above, or 27 or above with a weight-related condition such as high blood pressure, high cholesterol, prediabetes, obstructive sleep apnoea or cardiovascular disease. Lower thresholds may apply for some ethnic backgrounds under UK guidance. But licensing criteria are a starting point, not a guarantee of suitability; a prescriber looks at your full picture, including other medicines you take, your medical history and your goals.
If you are curious about how Wegovy compares to tirzepatide (the dual-agonist alternative licensed under the Mounjaro brand) the treatment overview page sets out the key differences in plain terms. The clinical evidence and the mechanism of action differ meaningfully, and understanding both can help you arrive at a consultation with better questions. You can also read more about how semaglutide produces its effects if the mechanism is something you want to understand before starting.
Wegovy is not recommended during pregnancy, breastfeeding or if you are actively trying to conceive. It is not licensed for under-18s. Anyone taking oral contraceptives alongside semaglutide should be aware that absorption may be affected and should discuss contraception with their prescriber. For anything not covered here, the general FAQ page is a useful starting point, and the support team is available seven days a week.
At nume, every consultation is personally reviewed by a GPhC-registered Independent Prescriber, a named clinician, not an automated filter. If you have been considering Wegovy for a while but are still working out how to go about getting it for weight loss, a free consultation is the right first step, and you can also find a plain-language guide to how you take Wegovy to help you feel prepared before you begin.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.